Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8320163rdf:typepubmed:Citationlld:pubmed
pubmed-article:8320163lifeskim:mentionsumls-concept:C1512409lld:lifeskim
pubmed-article:8320163lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:8320163lifeskim:mentionsumls-concept:C0079866lld:lifeskim
pubmed-article:8320163lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:8320163lifeskim:mentionsumls-concept:C0442821lld:lifeskim
pubmed-article:8320163lifeskim:mentionsumls-concept:C0217623lld:lifeskim
pubmed-article:8320163pubmed:issue5lld:pubmed
pubmed-article:8320163pubmed:dateCreated1993-7-30lld:pubmed
pubmed-article:8320163pubmed:abstractTextThe effects of 3-O-dodecylcarbomethylascorbic acid (3-O-DAsA), 3-O-ethylascorbic acid (3-O-EAsA) and 1-O-hexyl-2,3,5-trimethylhydroquinone (HTHQ) on 2-amino-6-methyldipyrido[1,2-a:3',2'-d]-imidazole (Glu-P-1)-induced mutagenesis and hepatocarcinogenesis were examined. In a Salmonella assay, addition of 2.5 to 20.0 mg of HTHQ to Salmonella TA 98 in the presence of S-9 mixture dose-dependently inhibited Glu-P-1-induced mutagenesis. The highest dose showed a 99% reduction in revertants. 3-O-DAsA and 3-O-EAsA were without effect. In an animal study using the medium-term bioassay system for the detection of hepatocarcinogens or hepatopromoters in F344 male rats, treatment with Glu-P-1 alone was associated with a significant increase in the number and area of GST-P-positive foci (47.5 +/- 8.9 and 11.1 +/- 4.7, respectively). Combined treatment with 1.0% HTHQ significantly reduced the number and area of GST-P-positive foci (to 8.1 +/- 2.1 and 0.6 +/- 0.2) while 3-O-DAsA exerted marginal inhibition and 3-O-EAsA had no effect. On the other hand, all three of these compounds slightly enhanced the numbers and areas of foci when given alone. The results indicate that HTHQ is a potent chemopreventer of Glu-P-1-induced hepatocarcinogenesis.lld:pubmed
pubmed-article:8320163pubmed:languageenglld:pubmed
pubmed-article:8320163pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8320163pubmed:citationSubsetIMlld:pubmed
pubmed-article:8320163pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8320163pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8320163pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8320163pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8320163pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8320163pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8320163pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8320163pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8320163pubmed:statusMEDLINElld:pubmed
pubmed-article:8320163pubmed:monthMaylld:pubmed
pubmed-article:8320163pubmed:issn0910-5050lld:pubmed
pubmed-article:8320163pubmed:authorpubmed-author:SugimuraTTlld:pubmed
pubmed-article:8320163pubmed:authorpubmed-author:AkagiKKlld:pubmed
pubmed-article:8320163pubmed:authorpubmed-author:HasegawaRRlld:pubmed
pubmed-article:8320163pubmed:authorpubmed-author:ItoNNlld:pubmed
pubmed-article:8320163pubmed:authorpubmed-author:HiroseMMlld:pubmed
pubmed-article:8320163pubmed:authorpubmed-author:MikiTTlld:pubmed
pubmed-article:8320163pubmed:authorpubmed-author:SatohTTlld:pubmed
pubmed-article:8320163pubmed:authorpubmed-author:NihroYYlld:pubmed
pubmed-article:8320163pubmed:issnTypePrintlld:pubmed
pubmed-article:8320163pubmed:volume84lld:pubmed
pubmed-article:8320163pubmed:ownerNLMlld:pubmed
pubmed-article:8320163pubmed:authorsCompleteYlld:pubmed
pubmed-article:8320163pubmed:pagination481-4lld:pubmed
pubmed-article:8320163pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8320163pubmed:meshHeadingpubmed-meshheading:8320163-...lld:pubmed
pubmed-article:8320163pubmed:meshHeadingpubmed-meshheading:8320163-...lld:pubmed
pubmed-article:8320163pubmed:meshHeadingpubmed-meshheading:8320163-...lld:pubmed
pubmed-article:8320163pubmed:meshHeadingpubmed-meshheading:8320163-...lld:pubmed
pubmed-article:8320163pubmed:meshHeadingpubmed-meshheading:8320163-...lld:pubmed
pubmed-article:8320163pubmed:meshHeadingpubmed-meshheading:8320163-...lld:pubmed
pubmed-article:8320163pubmed:meshHeadingpubmed-meshheading:8320163-...lld:pubmed
pubmed-article:8320163pubmed:meshHeadingpubmed-meshheading:8320163-...lld:pubmed
pubmed-article:8320163pubmed:meshHeadingpubmed-meshheading:8320163-...lld:pubmed
pubmed-article:8320163pubmed:meshHeadingpubmed-meshheading:8320163-...lld:pubmed
pubmed-article:8320163pubmed:meshHeadingpubmed-meshheading:8320163-...lld:pubmed
pubmed-article:8320163pubmed:meshHeadingpubmed-meshheading:8320163-...lld:pubmed
pubmed-article:8320163pubmed:meshHeadingpubmed-meshheading:8320163-...lld:pubmed
pubmed-article:8320163pubmed:year1993lld:pubmed
pubmed-article:8320163pubmed:articleTitleStrong inhibition of 2-amino-6-methyldipyrido[1,2-a:3',2'-d] imidazole-induced mutagenesis and hepatocarcinogenesis by 1-O-hexyl-2,3,5-trimethylhydroquinone.lld:pubmed
pubmed-article:8320163pubmed:affiliationFirst Department of Pathology, Nagoya City University, Medical School.lld:pubmed
pubmed-article:8320163pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8320163pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed